This site is intended for healthcare professionals
News

FDA approval for Trikafta in children with cystic fibrosis ages 6 through 11 with a certain mutation.- Vertex

Read time: 1 mins
Last updated:10th Jun 2021
Published:10th Jun 2021
9 June 2021-Vertex Pharmaceuticals Incorporated announced the FDA approved expanded use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (CF) ages 6 through 11 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive to Trikafta based on in vitro data.
Condition: Cystic Fibrosis-F508del-gene
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest